Shivani Dhir
Marietta, GANPI 1801580980
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,179 of the $13,933 with a category attached, or 87.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $7,131, 7.7 times the $928 reported in 2023.
Across 408 payments — averaging $34.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$1K
- Dermavant Sciences, Inc.$953
- LEO Pharma Inc.$919
- plus $6K from 25 others
What the payments were for
- Consulting fees$1,1408%
- Food & beverage$12,17987%
- Education$6144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 38 | $1,949 |
| Sanofi | 37 | $1,612 |
| Regeneron Healthcare Solutions, Inc. | 36 | $1,451 |
| AbbVie | 41 | $1,217 |
| Dermavant Sciences, Inc. | 16 | $953 |
| LEO Pharma Inc. | 20 | $919 |
| Arcutis Biotherapeutics, Inc. | 32 | $916 |
| Sun Pharmaceutical Industries Inc. | 24 | $608 |
| E.r. Squibb & Sons, L.L.C. | 28 | $585 |
| Johnson & Johnson | 8 | $542 |
| Lilly USA, LLC | 21 | $509 |
| Novartis | 24 | $421 |
| Pfizer | 19 | $327 |
| Galderma Laboratories, L.p. | 15 | $318 |
| Amgen | 10 | $253 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $209 |
| Sanofi-aventis U.S. LLC | 2 | $187 |
| Janssen Scientific Affairs, LLC | 2 | $152 |
| Merz North America, Inc. | 1 | $150 |
| Botanix SB Inc | 8 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $112 |
| Incyte Corporation | 4 | $103 |
| Organon | 5 | $98 |
| Boehringer Ingelheim | 2 | $43 |
| Convatec Inc. | 2 | $37 |
| Verrica Pharmaceuticals Inc. | 1 | $27 |
| Tempus AI, Inc | 1 | $23 |
| Surgenex LLC | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 11 | $123,141 |
| Dupixent PenDupilumab | 11 | $40,999 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.